Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients (Q43988022)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

13

object named as

Naoya Sakamoto

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Hiroaki Saito

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Kiyoaki Ito

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Masaya Sugiyama

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Teppei Matsui

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Yoshihiko Aoki

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Masatoshi Imamura

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Kazumoto Murata

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Naohiko Masaki

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Hideyuki Nomura

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Hiroshi Adachi

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Shuhei Hige

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Nobuyuki Enomoto

12

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Masayuki Kurosaki

14

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Masashi Mizokami

15

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sumio Watanabe

16

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

publication date

26 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

42

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

958-965

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Global burden of disease (GBD) for hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

The effects of HCV infection and management on health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleuk

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Experimental and theoretical analysis of the invasive signal amplification reaction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

DNA methylation landscapes: provocative insights from epigenomics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

The relationship of DNA methylation with age, gender and genotype in twins and healthy controls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01013.X

21 January 2018

Identifiers

10.1111/J.1872-034X.2012.01013.X

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43988022&oldid=2105342095"